Top Banner
International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President , International Society For Heart and Lung Transplantation Editor-in-Chief, Journal of Heart and Lung Transplantation Herbert Berger Chair in Medicine, Professor and Head of Cardiology Assistant Dean for Clinical Services, University of Maryland School of Medicine Baltimore, MD Disclosures: consultant to Roche, Astellas, XDX, Novartis
25

International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Dec 15, 2015

Download

Documents

Meredith Crago
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

International Progress In Heart Transplantation

and The “Vienna Factor”

Mandeep R. Mehra, MDPresident , International Society For Heart and Lung Transplantation

Editor-in-Chief, Journal of Heart and Lung TransplantationHerbert Berger Chair in Medicine, Professor and Head of CardiologyAssistant Dean for Clinical Services, University of Maryland School of

MedicineBaltimore, MD

Disclosures: consultant to Roche, Astellas, XDX, Novartis

Page 2: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

The Fascination With Transplantation Has Existed For Centuries

Page 3: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

• Scientific Exchange

• Financial pressures

Page 4: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

1982: The Launch of the Society Journal

Page 5: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Medium of Progress

•The International Registry

•Guidelines and position Statements

Page 6: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Vienna HeroesWOLNER

WIESELTHALER

LAUFER

ZUCKERMANN

KLEPETKO

GRIMM

Page 7: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Vienna Contributions• Pharmacokinetics And Dynamics Of Novel

Immunosuppression

• Genomic And Proteomic Biomarkers For Cardiac Rejection And Cardiac Allograft Vasculopathy

• Novel Aspects Of Mechanical Circulatory Support

• International Advocacy

Page 8: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Specific Causes of Death One Year After Cardiac Transplantation

Kirklin JK, et al. J Thorac Cardiovasc Surg 2003; 125:881-90.

Time after transplant (years)

CRTD: 1990-1999, n = 7290

1 2 3 4 5 6

0.025

0.020

0.015

0.010

0.005

0.0007 8 9 10

De

ath

s / y

ea

r

RejectionInfectionNon-specific graft failureNeurologicSudden

Malignancy

Allograft CAD

Renal Failure

Page 9: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

MALIGNANCY POST-HEART TRANSPLANTATION FOR ADULTSCumulative Prevalence in Survivors (Follow-ups: April 1994 - June 2004)

123267115Other

Malignancy Type

15

40

423

625 (26.2%)

1757 (73.8%)

8-Year Survivors

Type Not Reported

Lymph

Skin

3947

115129

748249

1108 (16.1%)544 (3.1%)Malignancy (all types combined)

5753 (83.9%)17250 (96.9%)No Malignancy

5-Year Survivors

1-Year Survivors

Malignancy/Type

”Other” includes: prostate (11, 34, 21), adenocarcinoma (7, 4, 2), lung (5, 4, 1), bladder (4, 5, 5), sarcoma (3, 3, 1), breast (2, 8, 3), cervical (2, 4, 0), colon (2, 3, 3), and renal (2, 7, 2). Numbers in parentheses are those reported within 1 year, 5 years and 8 years, respectively.

ISHLT 2005J Heart Lung Transplant 2005;24: 945-982 9

Page 10: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Current Uncertainty and Future Research Regarding Malignancies in Heart Transplantation

• Relationship between different immunosuppressants and cancer risk

• Relationship between duration and intensity of immunosuppression and cancer risk

• Efficacy of low or minimal immunosuppression regimens

• Frequency of cancer screening

• Components of cancer screening

Hauptman PJ and Mehra MR. J Heart Lung Transplant. 2005;24(8):1111-3.

Page 11: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

3 months later

17-year-old heart transplant recipient

4 years post-transplantation

Page 12: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Immune factorsCellular rejection scoreAntibody-mediated rejectionBalance of immunosuppression

SMC EC

Non-immune factorsMode of brain deathIschemia reperfusion injuryHyperlipidemiaHypertensionCMV infectionDonor age

Denudinginjury

Non-denudinginjury

PDGF, FGF, IGFTGF-ß, TNF, IL-1

MHC-IIICAM, VCAM

IL-1, IL-2, IL-6, TNFPDGF, FGF, IGF, TGF-ß

Platelet

T-lymphocyte

Macrophage

Selectins

INFLAMMATION

Mehra MR. Am J Transplant 2006; 6:1248-56.

Page 13: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

What’s Different In These Two Studies ?

Page 14: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Maximal intimal thickness (MIT) predicts cardiac events

Intimal thickening (mm) Kobashigawa JA et al. J Am Coll Cardiol 2005; 45:1532-7.Mehra M et al. J Heart Lung Transplant 1995; 14:S207-11.

Tuzcu EM et al. J Am Coll Cardiol 2005; 45:1538-42.

0.35 0.50 1.000

Early

Mid

Late

Normal

SevereAbnormal

LowHighModerate

Risk of cardiac event

Post-transplantation

time

“Prognostically relevant”- High plaque burden- Link with cardiac events

Page 15: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

IVUS Findings Versus Survival in Heart Transplantation

Therapy Attenuation of Intimal

Thickening

Rejection Non – Immune Effects

Survival (Duration Studied)

Statins Modest Rejection with HDC

Lipids

CRP

Improved

(10 years)

Mycophenolate mofetil

Modest Rejection

with HDC

Neutral Improved

(3 years)

Everolimus / sirolimus

Marked Acute cellular rejection only

Less CMV

Worse triglycerides

and renal function

No improveme

nt

(4 years)

Mehra MR. Am J Transplant 2006Mehra MR. Am J Transplant 2006

Page 16: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Multi-Detector Coronary CTA• Sigurdsson G JACC

2006;48:772-8.– 16 slice, n=54 >1.5 mm

vessel, NPV 99%, PPV 81%

• Gregory SA AJC 2006;98:877-884.– 64 slice, n=20, IVUS and

QCA, IVUS NPV 77%, PPV 89%

• Limitations contrast, radiation

• Prognosis??

Page 17: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Adapted after: Medzhitov R, Janeway CA Jr: Science, 2002

Danger SignalsDrive subsequent

immune activation and Inflammation

Infection/Injury

Pathogen-associated molecular patterns (PAMPs)

Toll

APC

MHC/peptide Co-stimulator

TCR CD28

Activation of the adaptive immune response

Page 18: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

IMMUNOLOGICAL FACTORS

CLINICAL OUTCOME

Engraftment

“Danger Signals”IMMUNE ACTIVATION

RELATED INFLAMMATION

NON-IMMUNOLOGICAL FACTORS

VASCULOPATHY

“DANGER SIGNALS”

Page 19: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

To cease smoking is the easiest thing I ever did…..

I ought to know because I've done it a thousand times

Mark Twain, 1905

Page 20: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Tobacco Exposure After Heart Transplantation: How Frequent?

Mehra M et al. American Journal of Transplantation 2005

• In 86 consecutive heart transplant recipients, 28 had evidence of significant tobacco exposure

• 32.5% rate of recrudescence– 14 with urine positivity (denied exposure)– 12 admitted exposure and had urine positivity– 2 admitted to smoking but were not urine

positive

Page 21: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Smoking Kills The Cardiac Allograft

Botha et al. American Journal of Transplantation 2008

Page 22: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

The Cardiac Allograft Is Going Up In Smoke: A Call to Action

Mehra M et al. American Journal of Transplantation 2005Mehra M. American Journal of Transplantation 2008

• A Third of patients resume smoking after a heart transplant!

• Although advances in prevention of rejection allow median survival of 15 years, smokers reduce their average life span by 4.5 years

• Most deaths occur due to development of accelerated coronary artery disease and new cancers

Page 23: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

A B

C D

A: Normal proximal tubular epithelial cells from a rat without cigarette smoke exposure; B: Swollen tubular epithelial cells, vacuoles, damaged glomerulus and fibrosis in a rat exposed to cigarette smoke for 30 days; C: normal glomerulus and D: completely damaged glomerulus in a rat exposed to cigarette smoke

Page 24: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.
Page 25: International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.

Science is nothing but developed perception, interpreted intent,

common sense rounded out and minutely articulated

George Santayana, philosopher (1863 - 1952)